⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8651133 | 0.67 | — | — | |
| SCHEMBL901473 | 0.67 | — | — | |
| SCHEMBL6699728 | 0.67 | ALDH1A1 (0.31) | — | |
| SCHEMBL16289513 | 0.65 | — | — | |
| SCHEMBL2012194 | 0.65 | — | — | |
| SCHEMBL7220202 | 0.65 | — | — | |
| SCHEMBL1244817 | 0.65 | — | — | |
| SCHEMBL12261475 | 0.65 | TYR (0.45) | — | |
| SCHEMBL12086868 | 0.65 | TYR (0.45) | — | |
| SCHEMBL8368625 | 0.65 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11780849-B2 | Imino sulfanone inhibitors of ENPP1 | VOLASTRA THERAPEUTICS, INC. (US) | 2023-10-10 | — | — | US | disclosed |
| US-11780849-B2 | Imino sulfanone inhibitors of ENPP1 | VOLASTRA THERAPEUTICS, INC. (US) | 2023-10-10 | — | — | US | disclosed |
| CN-115996912-A | Iminothiolanone inhibitors of ENPP1 | 沃拉斯查疗法公司 | 2023-04-21 | — | — | CN | disclosed |
| US-20230002406-A1 | IMINO SULFANONE INHIBITORS OF ENPP1 | VOLASTRA THERAPEUTICS, INC. (US) | 2023-01-05 | — | — | US | disclosed |
| WO-2021225969-A1 | IMINO SULFANONE INHIBITORS OF ENPP1 | VOLASTRA THERAPEUTICS, INC. (US) | 2021-11-11 | — | — | WO | disclosed |
| US-20040063780-A1 | Pharmaceutical preparations for treatment of type II diabetes and methods for treatment of type II diabetes | CHUGAI SEIYAKU KABUSHIKI KAISHA | 2004-04-01 | — | — | US | disclosed |